Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Mumbai Biggest Kala Ghoda Art Festival 2026 Returns With 'A Movable Feast': What's On The Food Menu?
Netherlands Women Qualify For ICC T20 World Cup 2026; Players Slide On Rain-Soaked Pitch Cover To Celebrate | Watch VIDEO
'Illegal Sand Mining Involves Leaders Across Parties': Karnataka Home Minister Dr G Parameshwar
UP Police Constable Recruitment 2026: Registration Process For 32,679 Posts Ends Soon At upprpb.in; Check Salary Structure & Other Important Details Here
